Olopatadine/mometasone
Combination drug
From Wikipedia, the free encyclopedia
Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older.[1][4][5] It contains olopatadine hydrochloride and mometasone furoate monohydrate.[1][4] It is sprayed into the nose.[1][4]
| Clinical data | |
|---|---|
| Trade names | Ryaltris |
| Other names | GSP 301 |
| AHFS/Drugs.com | Ryaltris |
| License data | |
| Pregnancy category |
|
| Routes of administration | Nasal spray |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Common side effects include an unpleasant taste (dysgeusia).[1]
It was approved for medical use in Australia in December 2019,[1][6] and in the United States in January 2022.[4]
